Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort studyResearch article Published on 2022-07-012022-10-05 Journal: The Lancet Regional Health - Americas [Category] 바이오마커, [키워드] 28-day mortality assumed benefit Clinical outcome Cohort cohort study comparable cost-effectiveness Covid cytokine storm COVID-19 COVID-19 patient Critically ill Critically ill patient CRP demonstrated Dexamethasone dose equity family feasible finding fixed dose foundation funding groups Inflammation inhibitor interleukin-6 no significant difference pair-wise comparison Patient patients physiological response receiving reduce mortality reduction response Scholarship severe COVID-19 supported Taylor the patient threshold Tocilizumab treated with COVID-19 [DOI] 10.1016/j.lana.2022.100228 [Article Type] Research article